PP_1170x120_10-25-21

AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension

Lupin releases budesonide inhalation suspension

Lupin releases budesonide inhalation suspension

BALTIMORE — Lupin announced the launch of its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules in the U.S. market, having received an approval from the United States Food and Drug Administration earlier. Lupin’s budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5